HLA-DRA anticorps (C-Term)
Aperçu rapide pour HLA-DRA anticorps (C-Term) (ABIN2282978)
Antigène
Voir toutes HLA-DRA AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Réactivité croisée
- Humain
-
Réactivité croisée (Details)
- Calculated cross reactivity: Hu
-
Attributs du produit
- HLA Class 2 Antigen DRA, CT (HLA Class II Histocompatibility Antigen DR alpha Chain, HLA-DRA, HLA-DRA1, FLJ51114, MHC Class II Antigen DRA, MLRW)
-
Purification
- Purified by ammonium sulfate precipitation.
-
Immunogène
- Synthetic peptide selected from the C-terminal region of human HLA-DRA (KLH).
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Optimal working conditions should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Supplied as a liquid in PBS, 0.44 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- -20°C
-
-
- HLA-DRA (HLA Class II DR alpha (HLA-DRA))
-
NCBI Accession
- NP_061984
-
UniProt
- P01903
-
Pathways
- TCR Signaling, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
Antigène
-